Chinese Patent Medicine Industry Report 2013 – 2016 : Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2016
Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance with specified prescription and standard. Chinese patent medicine industry covers the upstream Chinese herbal medicine production and preliminary processing, the middle pharmaceutical sectors as well as downstream commercial institutions of drug circulation and sales.
Currently, the State is enhancing its support for the Chinese patent medicine industry, successively introducing the Continuing Improving TCM Healthcare Policy, Notice on Conducting Construction of Key Projects of TCM Trade in Services and other favorable policies in 2013. In 2010-2013, China’s Chinese patent medicine industry developed rapidly, with revenue soaring from RMB215.4 billion to RMB448.2 billion at a CAGR of 27.7%.
According to hospital terminal data, Chinese patent medicine for the treatment of cardiovascular and cerebrovascular diseases, tumor diseases and respiratory system diseases are the top three categories of Chinese patent medicine in China, respectively accounting for 37.2%, 15.4% and 11.1% market share in 2012-2013. As far as the distribution of Chinese patent medicine formulations is concerned, there is a clear trend of convergence in injection, and injection formulation products in the top three categories of Chinese patent medicine all made up above 50%.
Cardiovascular and cerebrovascular disease market is the biggest market for Chinese patent medicine, but also the most-variety field with item sales of over RMB500 million. The representative products include ginkgo leaf injection, Shuxuetong injection, Danhong injection, Xingnao injection, and more.
In the international market, there is a higher recognition of Chinese patent medicine in Asia, especially in Southeast Asia, and many varieties of Chinese patent medicine are included in the Medicare drug list stipulated by Southeast Asian countries, and special departments are established for management research as well. But in the U.S. and European markets, affected by access restrictions and differences in medical health concept, Chinese patent medicine is still only sold as health care product. However, the international market sees strong demand for plant extracts (mostly traditional Chinese medicinal materials) whose export value in 2010-2013 grew at a CAGR of 44% and accounted for approximately 50% of China’s TCM export value.
Table of Content
1. Overview of Chinese Patent Medicine
1.1 Definition and Characteristics
1.2.1 Classification by Dosage Form
1.2.2 Classification by Pharmacology
1.2.3 Industry Chain
2. Operating Environment for Chinese Patent Medicine Industry
2.1.1 Domestic Policies
2.1.2 Foreign Policies
2.2 Consumer Trends
2.3 Industry Trends
3. Chinese Patent Medicine Market
3.1 Development Status
3.2.1 Regional Demand
3.2.2 Product Demand Structure
3.3.1 Yield Analysis and Key Areas
3.3.2 Industry Concentration
3.4 Regional Analysis of Players
3.5 Import and Export
3.5.3 Import-Export Structure
3.6 Traditional Chinese Medicinal Materials
3.6.2 Price Trend
3.7 Traditional Chinese Medicine Decoction Pieces (Chinese Herbal Medicines for Primary Processing)
3.7.1 Industry Status
3.7.2 Industry Trends
3.8 Plant Extract
3.8.1 Development Status
3.8.2 Import and Export
4. Chinese Patent Medicine Market Segments in China
4.1 Chinese Patent Medicine for Cardiovascular and Cerebrovascular Diseases
4.2 Chinese Patent Medicine for Tumor Diseases
4.3 Chinese Patent Medicine for Respiratory System Diseases
4.4 Chinese Patent Medicine for Musculoskeletal Diseases
5. Key Enterprises
5.1 Tianjin Tasly Pharmaceutical Co., Ltd.
5.1.3 Revenue Structure
5.1.4 Gross Margin
5.2 Guizhou Yibai Pharmaceutical Co., Ltd.
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.3 Yunnan Baiyao Group Co., Ltd.
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.4 Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.5 Shandong Dong-E E-Jiao Co., Ltd.
5.5.3 Revenue Structure
5.5.4 Gross Margin
5.6 China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu)
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.7 Shanghai Kaibao Pharmaceutical Co., Ltd.
5.7.3 Revenue Structure
5.7.4 Gross Margin
5.8 Kangmei Pharmaceutical Co., Ltd.
5.8.3 Revenue Structure
5.8.4 Gross Margin
5.9 Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
5.9.3 Revenue Structure
5.9.4 Gross Margin
5.10 Beijing Tongrentang Co., Ltd. (TRT)
5.10.3 Revenue Structure
5.10.4 Gross Margin
6. Summary and Forecast
6.1 Comparison of Domestic Key Chinese Patent Medicine Enterprises
6.1.2 Gross Margin
6.2 Industry Forecast
6.2.1 Industry Trends
6.2.2 Market Forecast
Sterilization equipment and disinfectants are essential procedures for infection control in healthcare facilities such as hospitals, clinics and laboratories. Increase in hospital acquired infections has compelled medical professionals to take strict regulatory actions to cure these infections with the use of various sterilization equipment and disinfectants. This factor will trigger the growth of sterilization equipment and disinfectants market during the forecast period. In addition, rise in geriatric population and increase in the number of surgeries performed at hospitals and clinics will further drive the growth of this market. The market for sterilization equipment can be segmented as: by product (heat, low temperature, radiation and filtration sterilization) and by application (life sciences, medical devices and pharmaceuticals). The disinfectants market has been segmented based on types (low, intermediate and high level, oxidizing and non-oxidizing disinfectants). The report includes market estimations in terms of revenue (USD million) for the global sterilization equipment and disinfectants market for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2013 to 2019 for all the aforementioned segments and sub segments. In addition, current market trends and recent developments have been taken into consideration while determining the growth rate of the global sterilization equipment and disinfectants market.
Market forecast in terms of value (USD million) for the period 2013 to 2019 has been provided for four major geographic regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). Detailed qualitative analysis of the factors responsible for driving and restraining the growth of the sterilization equipment and disinfectants market and future opportunities are provided in the report. PESTLE analysis has also been done while estimating individual geographies in order to provide current as well as future status. A list of recommendations for existing as well as new entrants has been discussed in the study to help in decision making.
Some of the key players of the global sterilization equipment and disinfectants market include Getinge Group, STERIS Corporation, Nordion, Inc., Advanced Sterilization Products Services, Inc. and Synergy Health plc. Market players are profiled in this report on the basis of attributes such as company overview, financial overview, business strategies adopted by the companies to ensure sustainability and maximize profits and product portfolio, and recent developments.
The global Sterilization Equipment and Disinfectants market has been segmented as below:
Sterilization Equipment and Disinfectants Market, by Type
Sterilization equipment and disinfectants Market, by Applications
Sterilization equipment and disinfectants Market, by Geography
Continuous Glucose Monitoring Market 2013 – 2019: http://www.marketresearchreports.biz/analysis/168198
This report studies the current scenario as well as the future market potential for continuous glucose monitoring systems (CGMS) globally. The market for these CGMS has been segmented by major devices/brands, namely, Guardian Real Time CGM System, FreeStyle Navigator, Dexcom Seven Plus CGM System, Dexcom G4 Platinum, MiniMed Paradigm Revel/Veo System and others. The market for these systems has been extensively analyzed on the basis of factors such as their commercial launch, sales revenue, geographic presence, usage and technological developments. The market size and forecasts in terms of revenue (USD million) for each of these segments have been provided for the period 2011 to 2019, considering 2012 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2013 to 2019.
Geographically, the continuous glucose monitoring market has been classified into four segments namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market size and forecast for each region has been provided for the period 2011 to 2019 along with the CAGR (%) for the forecast period 2013 to 2019. The study also includes qualitative analysis of the competitive scenario in these regions. The market overview section of the report comprises qualitative analysis of the overall market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis.
The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global continuous glucose monitoring market, in terms of percentage share in 2012 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market shares. The report concludes with the profiles of major players in the global continuous glucose monitoring market such as Medtronic, Inc., Dexcom, Inc., Abbott Laboratories, Inc., Bayer AG, Nova Biomedical Corporation, Senseonics, Incorporated, GlySens, Incorporated and Insulet Corporation.